Arca Biopharma traded at $2.01 this Wednesday March 29th, decreasing $0.02 or 0.99 percent since the previous trading session. Looking back, over the last four weeks, Arca Biopharma lost 9.05 percent. Over the last 12 months, its price fell by 13.36 percent. Looking ahead, we forecast Arca Biopharma to be priced at 2.01 by the end of this quarter and at 1.83 in one year, according to Trading Economics global macro models projections and analysts expectations.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Daiichi Sankyo 4,781.00 141.00 3.04% 78.40%
Otsuka Holdings 4,211.00 -16.00 -0.38% -0.50%
Arca Biopharma 2.01 -0.02 -0.99% -13.36%
Amgen 241.03 2.55 1.07% -0.63%
Brainstorm Cell Therapeutics 2.44 0.60 32.61% -27.38%
Biogen 274.01 3.76 1.39% 29.84%
Bristol-Myers Squibb 68.18 -0.02 -0.03% -7.51%
Capricor Therapeutics 4.17 0.07 1.71% 20.87%
Cytokinetics 35.25 0.27 0.77% -3.50%
CytrRx Corporation 0.10 0.01 7.97% -72.14%
Gilead Sciences 81.29 0.32 0.40% 36.74%
GlaxoSmithKline 1,420.60 -0.40 -0.03% -14.46%
Laboratory Of America 221.82 1.14 0.52% -17.54%
Myriad Genetics 23.33 0.52 2.28% -8.58%
Pfizer 40.25 0.26 0.65% -22.25%
United Therapeutics 217.23 -1.69 -0.77% 23.69%

Indexes Price Day Year
USND 11926 210.16 1.79% -17.42%

Arca Biopharma
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is focused on development and commercialization of targeted therapies for cardiovascular diseases. The Company's lead product includes Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) and Gencaro(bucindolol hydrochloride). rNAPc2 (AB201) is a treatment for diseases caused by ribonucleic acid (RNA), viruses, focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus. Gencaro(bucindolol hydrochloride) is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties for the treatment of atrial fibrillation (AF) in patients with heart failure. AF is the form of cardiac arrhythmia, a disruption of the heart’s normal rhythm or rate. The Company is conducting Phase II b clinical trial of rNAPc2 (AB201), ASPEN-COVID-19. It is also conducting Phase IIB/III clinical trial of Gencaro.